Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632184 | 0.87 | MAPT (0.33) | GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL8137202 | 0.71 | MAPT (0.37) | GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL31301236 | 0.67 | MAPT (0.38) | GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL1286805 | 0.67 | MAPT (0.38) | GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL3363708 | 0.67 | IDO1 (0.38) | GAAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL27965612 | 0.66 | MAPT (0.36) | GAAMAPTALDH1A1 | |
| SCHEMBL29563963 | 0.66 | MAPT (0.36) | MAPTKDM4E | |
| SCHEMBL6614914 | 0.66 | MAPT (0.36) | MAPTKDM4E | |
| SCHEMBL6614912 | 0.66 | MAPT (0.36) | MAPTKDM4E | |
| Urea SCHEMBL974632 | 0.64 | GAA (0.43) | GAAMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |